Meeting Banner
Abstract #4077

Evaluation of Imatinib Mesylate as a Possible Treatment for Nephrogenic Systemic Fibrosis in a Rat Model

MAGNA25Thomas A. Hope1, Philip LeBoit2, Whitney A. High3, Yanjun Fu4, Robert C. Brasch4

1Radiology and Biomedical Imaging, UCSF, San Francisco, CA, United States; 2Dermatology, UCSF, San Francisco, CA; 3Dermatology, University of Colorado, Denver, CO; 4Radiology, UCSF, San Francisco, CA

We have evaluated the efficacy of imatinib mesylate for the treatment of nephrogenic systemic fibrosis in a high dose GBCA animal model and have demonstrated that the administration of imatinib results in decreased lesion severity suggesting that imatinib may be effective in the treatment of NSF in humans.

Abstract PDF E-Poster Video

Keywords

administered administration alone amount analyzed animals biomedical biopsies came cell cells concomitant consecutive control counts days decided decreased deep deposited dermal dermatology dermis design dextrose dose effective efficacy evaluate evaluation fibroblast fibrosis five gadolinium histology hope humans improvement injected injection invest iron lesion lesions like limited marked materials measure measured model nuclei portion positive prevention previously promising protocol published radiology randomly rats received report representative rows saline samples separated seven severity skin spindle stained stains stopped suggesting superficial systemic treated treating treatment upon versus week weeks worsened